CTOs on the Move


 
Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ignyta.com
  • 11111 Flintkote Avenue
    San Diego, CA USA 92121
  • Phone: 858.255.5959

Executives

Name Title Contact Details

Funding

Ignyta raised $42 M on 07/01/2016
Ignyta raised $160M on 10/25/2017

Similar Companies

Bio-Circle

Bio-Circle is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Curie Co

Curie Co is replacing chemicals with clean, sustainable proteins and enzymes.

CORRECT PHARMACY

CORRECT PHARMACY is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MicuRx Pharmaceuticals

MicuRx mission is to discover and develop safer and more convenient antibiotics to combat drug-resistant bacterial infections. Multi-drug resistant (MDR) infections represent a major global threat to the public health, routinely forcing the use of antibiotics with high incidence of adverse effects. To combat resistant infections, physicians may increase dosing of antibiotics, or resort to less safe agents, pushing the safety envelope. Thus, healthcare providers and regulatory agencies increasingly face a difficult choice of balancing the risk of infection against unacceptably high adverse event rates from an effective but relatively toxic antibiotic. For example, in July 2016, FDA imposed a new labeling warning on the toxicity of fluoroquinolones, further restricting the use of this essential class, exemplified by anti-pseudomonal agent ciprofloxacin. Anti-MRSA agent linezolid (Zyvox®) is often used beyond its approved 14-day therapy, resulting in several myelosuppression-associated adverse effects listed in the black box warning for this important drug. MicuRx is addressing the critical need for effective but safer therapeutics by designing novel new compounds with reduced toxicity and adverse events while maintaining excellent clinical efficacy.

Antibody Solutions

Antibody Solutions is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.